Network features suggest new hepatocellular carcinoma treatment strategies

BMC Systems Biology

Volumn 8, Issue 1, 2014, Pages

  Lavi, Orit ^a   Skinner, Jeff ^b   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Cancer therapy; Co expression network; Pathway network; Redundancy; Resistance; Robustness

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; SORAFENIB; TRANSCRIPTOME;

ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TRANSCRIPTOME;

EID: 84904771203     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/s12918-014-0088-0     Document Type: Article

References (52)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273. e1261, 22537432.
2. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002, 963:13-20. 12095924.
3. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005, 11:2320-2326. 15788683.
4. Wang E. Cancer systems biology 2010, CRC Press, Taylor & Francis Group, Boca Raton, FL.
5. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011, 140:1501-1512. e1502, 21320499.
6. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Sole M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008, 68:6779-6788. 18701503.
7. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392. 19723656.
8. Segal E, Friedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005, 37(Suppl):S38-S45. 15920529.
9. Ruan J, Dean AK, Zhang W: A general co-expression network-based approach to gene expression analysis: comparison and applications.BMC Syst Biol 2010, 4:8..
10. Aggarwal A, Guo DL, Hoshida Y, Yuen ST, Chu KM, So S, Boussioutas A, Chen X, Bowtell D, Aburatani H, Leung SY, Tan P. Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Res 2006, 66:232-241. 16397236.
11. Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of conserved genetic modules. Science 2003, 302:249-255. 12934013.
12. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P. Coexpression analysis of human genes across many microarray data sets. Genome Res 2004, 14:1085-1094. 15173114.
13. Horvath S, Dong J: Geometric interpretation of gene coexpression network analysis.PLoS Comput Biol 2008, 4:e1000117..
14. Bansal M, Belcastro V, Ambesi-Impiombato A, di Bernardo D: How to infer gene networks from expression profiles. Mol Syst Biol 2007, 3:78..
15. Langfelder P, Horvath S: WGCNA: an R package for weighted correlation network analysis.BMC Bioinformatics 2008, 9:559..
16. Tomfohr J, Lu J, Kepler TB: Pathway level analysis of gene expression using singular value decomposition.BMC Bioinformatics 2005, 6:225..
17. Efroni S, Schaefer CF, Buetow KH: Identification of key processes underlying cancer phenotypes using biologic pathway analysis.PLoS One 2007, 2:e425..
18. Langfelder P, Horvath S: Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol 2007, 1:54..
19. Siso-Nadal F, Fox JJ, Laporte SA, Hebert TE, Swain PS: Cross-talk between signaling pathways can generate robust oscillations in calcium and cAMP. PLoS One 2009, 4:e7189..
20. Li Y, Agarwal P, Rajagopalan D. A global pathway crosstalk network. Bioinformatics 2008, 24:1442-1447. 18434343.
21. Shao L, Wang L, Wei Z, Xiong Y, Wang Y, Tang K, Li Y, Feng G, Xing Q, He L: Dynamic network of transcription and pathway crosstalk to reveal molecular mechanism of MGd-treated human lung cancer cells. PLoS One 2012, 7:e31984..
22. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676. 15349906.
23. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284. 17126425.
24. Alon U. An introduction to systems biology: design principles of biological circuits 2006, Chapman & Hall/CRC, London.
25. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, Fan F, Jiao B, Xu G. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 2012, 11:4361-4372. 22768978.
26. Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, Xu J, Zheng S, Li L. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012, 11:1217-1227. 22200553.
27. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013, 58:229-238. 23463346.
28. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140:1410-1426. 21406195.
29. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255. 22353262.
30. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012, 3:236-260. 22470194.
31. Callaway DS, Newman ME, Strogatz SH, Watts DJ. Network robustness and fragility: percolation on random graphs. Phys Rev Lett 2000, 85:5468-5471. 11136023.
32. Liu YY, Slotine JJ, Barabasi AL. Controllability of complex networks. Nature 2011, 473:167-173. 21562557.
33. Nowak MA, Boerlijst MC, Cooke J, Smith JM. Evolution of genetic redundancy. Nature 1997, 388:167-171. 9217155.
34. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev 2012, 26:641-650. 22474259.
35. Korcsmaros T, Farkas IJ, Szalay MS, Rovo P, Fazekas D, Spiro Z, Bode C, Lenti K, Vellai T, Csermely P. Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery. Bioinformatics 2010, 26:2042-2050. 20542890.
36. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012, 109:6662-6667. 22451913.
37. Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, Ozkan E, Fernhoff NB, van de Rijn M, Weissman IL, Garcia KC. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013, 341:88-91. 23722425.
38. Johnson M, Sharma M, Henderson BR. IQGAP1 regulation and roles in cancer. Cell Signal 2009, 21:1471-1478. 19269319.
39. White CD, Brown MD, Sacks DB. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett 2009, 583:1817-1824. 19433088.
40. Schmidt VA: Watch the GAP: emerging roles for IQ motif-containing GTPase-activating proteins IQGAPs in hepatocellular carcinoma. Int J Hepatol 2012, 2012:958673..
41. Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF. Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol 2008, 28:1489-1502. 18180285.
42. Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era?. Ann Surg Oncol 2010, 17:1247-1256. 20405329.
43. Wu J, Zhu AX: Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011, 4:30..
44. Villanueva A, Llovet JM. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 2012, 18:1824-1826. 22355010.
45. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M: The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007, 3:e59..
46. Goh KI, Oh E, Kahng B, Kim D: Betweenness centrality correlation in social networks.Phys Rev E Stat Nonlin Soft Matter Phys 2003, 67:017101..
47. Edgington E. Randomization tests 1995, Marcel Dekker, New York.
48. Good P. Permutation, parametric, and bootstrap tests of hypotheses 2005, Springer, New York.
49. Kemper A. Valuation of network effects in software markets: a complex networks approach 2009, Springer-Verlag, Berlin.
50. Watts DJ, Strogatz SH. Collective dynamics of 'small-world' networks. Nature 1998, 393:440-442. 9623998.
51. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012, 40:D109-D114. 22080510.
52. Bounova G, de Weck O: Overview of metrics and their correlation patterns for multiple-metric topology analysis on heterogeneous graph ensembles. Phys Rev E Stat Nonlin Soft Matter Phys 2012, 85:016117..